ijerph-logo

Journal Browser

Journal Browser

Prostate Cancer Chemoprevention and Treatment

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Global Health".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 2787

Special Issue Editor


E-Mail Website
Guest Editor
Natural Chemotherapeutics Research Laboratory, NIH-Center for Environmental Health, College of Science,Engineering and Technology, Jackson State University, Jackson, MS ,USA
Interests: prostate cancer; chemoprevention; treatment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Prostate cancer (PCa) is the most common noncutaneous cancer and the second leading cause of cancer-related deaths in men. Of the nearly 75,000 men yearly undergoing a radical prostatectomy (RP) for localized PCa in the United States, nearly one-third of them will experience recurrent disease following surgery. The treatment decisions for PCa are based exclusively on histological architecture, prostate-specific antigen (PSA) levels, and local disease state. Despite advances in screening for and early detection of PCa, a large percentage of men continue to be diagnosed with metastatic disease, including about 20% of African American men, resulting in a high mortality rate within that population. Because aggressive metastatic lethal PCa is still largely incurable, there is an urgent need for the discovery and development of agents that are efficacious against this disease, in particular castration-resistant prostate cancer (CRPC).

Dr. Clement G. Yedjou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • chemoprevention
  • treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

8 pages, 1114 KiB  
Article
Prognostic Value of CD1B in Localised Prostate Cancer
by Cheng-Hsueh Lee, Lih-Chyang Chen, Chia-Cheng Yu, Wen-Hsin Lin, Victor C. Lin, Chao-Yuan Huang, Te-Ling Lu, Shu-Pin Huang and Bo-Ying Bao
Int. J. Environ. Res. Public Health 2019, 16(23), 4723; https://doi.org/10.3390/ijerph16234723 - 27 Nov 2019
Cited by 14 | Viewed by 2227
Abstract
Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed [...] Read more.
Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09–1.85, p = 0.010). In addition, rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression correlated with poorer BCR-free survival. Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification. Full article
(This article belongs to the Special Issue Prostate Cancer Chemoprevention and Treatment)
Show Figures

Figure 1

Back to TopTop